Liraglutide as Additional Treatment in Type 1 Diabetes

In continuation of my update on Liraglutide...

 Results of a small, observational study conducted at the University at Buffalo suggest that liraglutide (below structure) , an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control of their blood glucose levels.

More....

New drug more effective than standard treatment to prevent heart-attack deaths

In continuation of my update on ticagrelor .....

Robert Storey, Professor of Cardiology at the University of Sheffield's Department of Cardiovascular Science, presented findings today that confirm one in five deaths in the year following a heart attack could be prevented if a new drug, ticagrelor (see structure), was used instead of the standard treatment, clopidogrel...

More...

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

We know that, PLX-4032(RG7204, Vemurafenib) is a highly selective inhibitor of BRAF kinase activity, with an IC50 of 44 nmol/L against V600E-mutant BRAF. BRAFV600E cancer-causing mutation occurs in most melanomas and about eight percent of all solid tumors....

More....

Formoterol drug improves fat burning and protein metabolism in men

We know that, Formoterol  or eformoterol  is a long-acting β₂-agonist used in the management of asthma and/or chronic obstructive pulmonary disease (COPD). It is marketed in four forms: a dry-powder inhaler (DPI), a metered-dose inhaler (MDI), an oral tablet, and an inhalation solution, under various trade names including Foradil/Foradile (Schering-Plough in the U.S., Novartis rest of world), Oxeze (AstraZeneca), Atock (Astellas), Atimos Modulite (Trinity-Chiesi), and Perforomist (Dey).

Now researchers lead by Dr. Paul Lee of  Garvan Institute of Medical Research in Sydney, have for the first time reports that research in animals has shown that formoterol can stimulate the growth of muscle and the burning of fat...

Formoterol drug improves fat burning and protein metabolism in men

Lyxumia®, as an add-on to basal Insulin, shows significant positive phase III results

Sanofi  announced today that new results from a Phase III study showed that the investigational product Lyxumia® (lixisenatide see structure above), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patientswith type 2 diabetes without significantly increasing their risk of hypoglycemia...

More...

Airtel: Switch off Diesel

Hi ,

I just signed a petition opposing Airtel's use of dirty diesel energy to power their cell phone towers.

Please read the mail below and take action.

Regards,

---

Dear friends,

Thanks to the telecommunications sector, every new call and SMS is hurting our environment. Lakhs of massive mobile network towers in our country run on dirty diesel.

Airtel is the market leader and trend-setter of the Indian telecom industry. If we get them to switch to renewable energy, it will set an example for the others to follow. Customers are the mainstay of this industry. Airtel would notice if customers ask them to make their calls green by using clean energy to power company’s mobile towers.

You should ask Airtel to switch to renewable energy.

http://www.greenpeace.org/india/en/What-We-Do/Stop-Climate-Change/Green-Electronics/switch-off-diesel/airtel-switch-off-diesel/

Several current and potential Airtel subscribers, asking them to switch to renewable energy will help put pressure on them to act. Since the company is bound to provide good service to its subscribers, they will not be able to ignore this feedback.

Like coal and nuclear, oil too is an unsustainable energy option. The Deepwater Horizon oil spill last year showed the dangers of our addiction to oil.^[2] Studies conducted by the Intergovernmental Panel on Climate Change have shown that renewable energy is capable of powering the world.^[3] Airtel needs to realise this and quit dirty energy.

Tell them now.

http://www.greenpeace.org/india/en/What-We-Do/Stop-Climate-Change/Green-Electronics/switch-off-diesel/airtel-switch-off-diesel/

Thanks a billion!



Abhishek Pratap
Climate and Energy Campaigner
Greenpeace India

---

Sources:

1. Dirty Talking? Case for telecom to shift from diesel to renewable, Greenpeace India, May 19, 2011
http://www.greenpeace.org/india/Global/india/docs/cool-it/reports/telecom-report-may-2011.pdf [PDF]

2. BP Oil Spill: How Bad Is Damage to Gulf One Year Later? Time magazine, April 19, 2011
http://news.yahoo.com/s/time/20110419/hl_time/08599206603100

3. Renewable energy can power the world, says landmark IPCC study, Guardian, May 9, 2011
http://www.guardian.co.uk/environment/2011/may/09/ipcc-renewable-energy-power-worlddr.umesh1969@gmail.com

You are receiving this email because someone you know sent it to you from the Greenpeace site. Greenpeace retains no information about individuals contacted through its site, and will not send you further messages without your consent -- although your friends could, of course, send you another message.

New drugs (Victrelis and Incivek ) encouraging for African Americans with hepatitis C

Current standard of treatment of interferon and ribavirun has only been effective in curing 38 to 40 percent of patients with chronic hepatitis C genotype 1. In clinical trials, Victrelis and Incivek, when working in concert with interferon and ribavirun, cured 65 to 75 percent of people with chronic disease and Victrelis-alone doubled the previous cure rate among African Americans......

Victrelis (Boceprevir)             

                                                                                                                                                                                                                                      Incivek (Telaprevir)


News Release Archives > New drugs encouraging for African Americans with hepatitis C

UCB,s new data for Cimzia® (certolizumab pegol) showed a rapid clinical response across a broad population of RA patients

UCB, announced data which showed that the addition of Cimzia^® (certolizumab pegol) to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients. Company also claims that, consistent efficacy was observed across patients taking certolizumab pegol whether they had previously received TNF inhibitors or not and whether they received certolizumab pegol monotherapy or with concomitant DMARDs.....

UCB Media Centre - New data for Cimzia® (certolizumab pegol) showed a rapid clinical response across a broad population of rheumatoid arthritis (RA) patients

Curcumin compound improves effectiveness of head and neck cancer treatment, study finds

In continuation of my update on Curcumin and its usefulness....

Curcumin compound improves effectiveness of head and neck cancer treatment, study finds

Incivek Approved for Hepatitis C

In continuation of my update on telaprevir...
Incivek Approved for Hepatitis C: "MONDAY, May 23 -- Incivek (telaprevir) has been approved by the U.S. Food and Drug Administration for adults with chronic hepatitis C infection who either haven't received standard interferon therapy or haven't responded to it.

MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults

Levadex is designed to be differentiated from existing migraine treatments. It is a novel formulation of dihydroergotamine (see above structure, DHE), a drug used intravenously in clinical settings to effectively and safely treat migraines.

 MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults

Gout drug success for Novartis

Canakinumab (trade name Ilaris, previously ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.

We know that, Canakinumab was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS) by the US FDA on June 2009 and by the European Medicines Agency in October 2009. CAPS is a spectrum of autoinflammatory syndromes including familial cold autoinflammatory syndrome, Muckle–Wells syndrome, and neonatal-onset multisystem inflammatory disease.

Canakinumab was being developed by Novartis for the treatment of rheumatoid arthritis but this trial has been discontinued. Canakinumab is also in phase I clinical trials as a possible treatment for chronic obstructive pulmonary disease.

Gout drug success for Novartis

'Turkey tail' mushroom effectively suppresses prostate tumour development

We Know that, Turkey tail/Trametes versicolor — formerly known as Coriolus versicolor and Polyporus versicolor is an extremely common polypore mushroom which can be found throughout the world. Versicolor means 'of several colours' and it is true that this mushroom is found in a wide variety of different colours. T. versicolor is commonly called Turkey Tail because of its resemblance to the tail of the wild turkey. T. versicolor is recognized as a medicinal mushroom in Chinese medicine under the name yun zhi. In China and Japan T. versicolor is used as in immunoadjuvant therapy for cancer. Now Queensland University of Technology (QUT) researchers reported that, the mushroom  has the  medicinal benefits up to  100 per cent effective in suppressing prostate tumour development in mice during early trials......

'Turkey tail' mushroom effectively suppresses prostate tumour development

Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study

In continuation of my update on Linezolid and Vancomycin...

Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study

Coffee reduces prostate cancer risk

Coffee reduces prostate cancer risk